- Home
- YQ vs NRSN Comparison
YQ vs NRSN Comparison
Compare YQ & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YQ | NRSN |
|---|---|---|
| Founded | 2012 | 2017 |
| Country | China | Israel |
| Employees | N/A | 16 |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.7M | 26.5M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | YQ | NRSN |
|---|---|---|
| Price | $2.67 | $0.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 6.2K | ★ 135.9K |
| Earning Date | 06-09-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $583.67 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.70 | $0.63 |
| 52 Week High | $6.45 | $2.60 |
Technical Indicators
Market Signals| Indicator | YQ | NRSN |
|---|---|---|
| Relative Strength Index (RSI) | 63.35 | 74.97 |
| Support Level | $2.55 | $0.84 |
| Resistance Level | $3.68 | $1.06 |
| Average True Range (ATR) | 0.24 | 0.05 |
| MACD | 0.07 | 0.03 |
| Stochastic Oscillator | 70.16 | 100.00 |
Price Performance
Historical ComparisonAbout YQ 17 Education & Technology Group Inc.
17 Education & Technology Group Inc is an education technology company in China. It offers smart, in-school, teaching and learning SaaS offerings assist students, teachers, schoolmasters and educational authorities across China. It also offer other educational products and services that complement students' in-school learning. Geographically group operates in China.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.